News
-
-
-
PRESS RELEASE
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Immunic's Oral IMU-856 shows dose-dependent increase of GLP-1 in celiac disease patients, potential as oral weight management treatment. New data presented in webcast -
-
-
-
-
-
-